Total item
Cart Subtotal
$0.00 FLT3
| Catalog No. | Inhibitor Name | FLT3 | Other |
|---|---|---|---|
| A10996 | Cabozantinib | ** | VEGFR2/KDR,c-Met,Kit |
| A10027 | Quizartinib | *** | |
| A11411 | Dovitinib | **** | c-Kit,VEGFR3/FLT4,FGFR1 |
| A10610 | Amuvatinib | * | c-Kit (D816H),PDGFRα (V561D) |
| A10887 | Tandutinib | * | c-Kit,PDGFRβ,CSF-1R |
| A11180 | TG101209 | * | JAK2,RET,JAK3 |
| A10508 | KW-2449 | **** | Abl (T315I),Abl,FGFR1 |
| A10352 | ENMD-2076 | *** | RET,Aurora A,VEGFR3/FLT4 |
| A10198 | Dovitinib Dilactic Acid | **** | c-Kit,FGFR1,VEGFR3/FLT4 |
| A12694 | Pacritinib | ** | JAK2 (V617F),JAK2,TYK2 |
| A12427 | TCS 359 | * | |
| A10352 | ENMD-2076 L-(*)-Tartaric acid | RET,Aurora A,VEGFR3/FLT4 | |
| A15904 | UNC2025 | **** | Mer |
| A14025 | AMG 925 | **** | CDK4,CDK1 |
| A14214 | G-749 | **** | Mer,Aurora B,RET |
| A14156 | AZD2932 | PDGFRβ,VEGFR-2,c-Kit | |
| A10769 | R406 | Syk | |
| A12419 | Go6976 | JAK2,PKCα,PKCβ1 | |
| A11962 | TG-02 (SB1317) | * | CDK2, JAK2 |
| A14411 | Gilteritinib (ASP2215) | **** | Axl |
| A15003 | AST 487 | Ret, c-Kit, KDR, c-Abl | |
| A15520 | Pexidartinib (PLX3397) | * | Kit, CSF-1R |
| A15548 | SU5614 | ||
| A16248 | BPR1J-097 | ** |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
44 Item(s)
per page
-
FLT3-IN-1
Catalog No. A16249 FLT3 inhibitorFLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM. Learn More -
G-749
Catalog No. A14214 FLT3 inhibitorG-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y). Learn More -
Gilteritinib (ASP2215)
Catalog No. A14411 FLT3/Axl inhibitorGilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. Learn More -
AMG-925
Catalog No. A14025 Dual FLT3/CDK4 inhibitorAMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. Learn More -
Pexidartinib (PLX3397)
Catalog No. A15520 CSF1/Kit/FLT3 inhibitorPexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. Learn More -
SU5614
Catalog No. A15548 FLT3 inhibitorSU5614 is a potent and selective FLT3 inhibitor. SU5614 reverts the antiapoptotic and pro-proliferative activity of FLT3 ligand (FL) in FL-dependent cells. Learn More -
UNC-2025
Catalog No. A15904 Dual MER/FLT3 inhibitorUNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3. Learn More -
AC710 Mesylate
Catalog No. A16246 FLT3/KIT/PDGFRα/PDGFRβ inhibitorAC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively. Learn More -
BPR1J-097
Catalog No. A16248 FLT3 inhibitorBPR1J-097 is a novel small molecule FLT-3 inhibitor with promising in vivo anti-tumour activities. Learn More -
XL184 free base (Cabozantinib)
Catalog No. A10996 VEGFR inhibitorXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. Learn More -
FLT3-IN-2
Catalog No. A16250 -
CCT241736
Catalog No. A21097 dual FLT3/Aurora kinase inhibitorCCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor. Learn More -
CG-806
Catalog No. A19814 FLT3/BTK inhibitorCG-806 is an orally active, potent and non-covalent pan-FLT3/pan-BTK inhibitor with an IC50 of 0.08 μM for FLT3. CG-806 has an IC50 of 11 nM against FLT3 wild type (WT)-transfected Ba/F3 cells. Learn More -
FLT3-IN-3
Catalog No. A20172 FLT3 inhibitorFLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively. Learn More -
TAK-659
Catalog No. A20450 SYK/FLT3 inhibitorTAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. Learn More -
5'-Fluoroindirubinoxime
Catalog No. A22692 FLT3 inhibitor5'-Fluoroindirubinoxime (5??-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM. Learn More -
HM-43239
Catalog No. A20826 FLT3 inhibitorHM-43239 is a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations Learn More -
SEL24-B489 HCl
Catalog No. A22203 pan-PIM/FLT3 inhibitorSEL24-B489 HCl is a potent, dual pan-PIM/FLT3 inhibitor. Learn More -
AC220 (Quizartinib)
Catalog No. A10027 FLT3 inhibitorAC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively. Learn More -
Pacritinib (SB1518)
Catalog No. A12694 JAK2/FLT3 inhibitorPacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Learn More -
Dovitinib (TKI-258)
Catalog No. A11411 RTK inhibitorDovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively. Learn More -
Crenolanib (CP-868596)
Catalog No. A11052 PDGFR/FLT3 InhibitorCrenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations. Learn More -
TG-02 (SB1317)
Catalog No. A11962 FLT3 inhibitorTG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Learn More -
MRX-2843
Catalog No. A16958 MERTK and FLT3 inhibitorMRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3. Learn More -
R406 besylate
Catalog No. A10769 Syk InhibitorR406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM. Learn More -
R406 (Tamatinib)
Catalog No. A10770 Syk InhibitorR406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM. Learn More -
MP470 (MP-470, Amuvatinib)
Catalog No. A10610 -
Tandutinib (MLN518)
Catalog No. A10887 FLT3 InhibitorTandutinib (MLN518) inhibits the autophosphorylation of FLT3, c-KIT and PDGF receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Learn More -
Gilteritinib hemifumarate
Catalog No. A18235 FLT3/AXL inhibitorGilteritinib hemifumarate is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. Learn More -
FN-1501
Catalog No. A13559 FLT3/CDK inhibitorFN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. Learn More -
FLT3-IN-4
Catalog No. A18509 FLT3 inhibitorFLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia. Learn More -
PROTAC FLT-3 degrader 1
Catalog No. A18682 FLT-3 ITD degraderPROTAC FLT-3 degrader 1 is an FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction. Learn More -
BSc5371
Catalog No. A19465 FLT3 inhibitorBSc5371 is a potent and irreversible FLT3 inhibitor, with Kds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. Learn More -
SB1317 (TG02)
Catalog No. A13454 CDK/JAK2/FLT3 inhibitorSB1317 is a potent inhibitor of Cyclin dependent kinases (CDKs), FMS-like tyrosine kinase-3 (FLT3) and Janus kinase 2 (JAK2) with IC50 values of 13nM, 56nM and 73nM for CDK2, JAK2 and FLT3, respectively. Learn More -
ENMD-2076
Catalog No. A10352 Aurora A / FLT3 InhibitorENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2. Learn More -
KW-2449
Catalog No. A10508 FLT3/FGFR/Bcr-Abl/Aurora InhibitorKW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. Learn More -
TG-101348 (Fedratinib, SAR302503)
Catalog No. A11082 JAK2/FLT3 inhibitorTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity. Learn More -
TG101209
Catalog No. A11180 JAK2 inhibitorTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Learn More -
Dovitinib Dilactic acid (TKI258 Dilactic acid)
Catalog No. A10198 RTK inhibitorDovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively. Learn More -
MK-2461
Catalog No. A11753 c-Met InhibitorMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Learn More -
Go 6976
Catalog No. A12419 PKC inhibitorGo6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3. Learn More -
AST 487
Catalog No. A15003 RET kinase inhibitorAST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret. Learn More -
TCS 359
Catalog No. A12427 FLT3 inhibitorTCS 359 is a potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases. Learn More -
AZD 2932
Catalog No. A14156 mutil-targeted protein tyrosine kinase inhibitorAZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively. Learn More
44 Item(s)
per page
FILTER BY:
Adooq Quality Guarantee
We promise all products perform as described.